Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD

Outlook Therapeutics, Inc. announced that the European Commission has granted Marketing Authorization for LYTENAVA, an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (AMD) in the EU.
[Outlook Therapeutics, Inc.]
Press Release